Evolent Health (EVH) Reports Q4: Everything You Need To Know Ahead Of Earnings

Evolent Health (EVH) Reports Q4: Everything You Need To Know Ahead Of Earnings

Kayode Omotosho

Mon, February 23, 2026 at 12:10 PM GMT+9 2 min read

In this article:

EVH

+0.72%

Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing earnings results this Tuesday after market close. Here’s what to expect.

Evolent Health beat analysts’ revenue expectations last quarter, reporting revenues of $479.5 million, down 22.8% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and EBITDA guidance for next quarter missing analysts’ expectations significantly.

Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Evolent Health’s revenue to decline 27.5% year on year, a reversal from the 16.3% increase it recorded in the same quarter last year.

Evolent Health Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Evolent Health’s peers in the healthcare technology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 2.3%, meeting analysts’ expectations, and Tandem Diabetes reported revenues up 15%, topping estimates by 4.9%. Omnicell traded down 20.6% following the results while Tandem Diabetes was up 32.7%.

Read our full analysis of Omnicell’s results here and Tandem Diabetes’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Evolent Health is down 24.8% during the same time and is heading into earnings with an average analyst price target of $8.50 (compared to the current share price of $2.79).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Terms and Privacy Policy

Privacy Dashboard

More Info